Spotlight -

B + L Dry Eye Series|

Transforming Glaucoma Management|

Zeiss Clinical Cases

Viewing

|Videos|May 5, 2021

Modern Retina Digital Edition

Modern Retina Summer 2021
Volume 1
Issue 1

Analyzing clinical results of dexamethasone implant effect on macular thickness

Author(s)David Hutton, Modern Retina Staff

Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.

Daniel F. Kiernan, MD, a vitreoretinal surgeon at The Eye Associates, Sarasota, Florida, discusses the highlights of his 2021 ARVO virtual presentation on the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on optical coherence tomography (OCT) testing following vitreoretinal surgery.

See more ARVO coverage

Articles in this issue

about 5 years ago

Article

Sustained-release anti-inflammatory therapy is valuable in noninfectious uveitis

about 5 years ago

Article

Pediatric ophthalmologists target inherited retinal diseases

over 5 years ago

Article

Gaining a greater understanding of AMD

over 5 years ago

Article

VEGF and beyond: therapeutic targeting in retinal vascular disorders

over 5 years ago

Article

Laser imaging system may offer early detection, treatment for eye diseases that cause blindness

Newsletter

Don’t miss out—get Modern Retina updates delivered straight to your inbox.

Related Content

Cynthia Toth, MD, of the Duke Department of Ophthalmology

Using OCT to predict neurodevelopmental risk in preterm infants: Cynthia Toth, MD

ByCytnthia Toth, MD,Lucia Gambuzza,Abigail Lewis, Content Intern

July 8th 2026

(Modern Retina) Could FLIO predict how fast geographic atrophy will grow?

Could FLIO predict how fast geographic atrophy will grow?

ByModern Retina Staff

July 4th 2026

(Modern Retina) Vaccinated patients show markedly lower risk of new-onset idiopathic uveitis

Vaccinated patients show markedly lower risk of new-onset idiopathic uveitis

ByModern Retina Staff

July 3rd 2026

Charles Wykoff, MD, PhD | Modern Retina Video

Revakinagene taroretcel-lwey for MacTel: Charles Wykoff, MD, PhD, on a year of real-world experience

ByCharles C. Wykoff, MD, PhD,Lucia Gambuzza

July 2nd 2026

(Image credit: Modern Retina) Optimizing anti-VEGF in AMD, DME, and RVO: Strategies for durable disease control

Optimizing anti-VEGF in AMD, DME, and RVO: Strategies for durable disease control

ByModern Retina Staff

June 30th 2026

Latest CME

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Neel Pasricha, MD; Asim V. Farooq, MD; Susana Campos, MD, MPH

Treatment Optimization in the Evolving Anti-VEGF Era

Treatment Optimization in the Evolving Anti-VEGF Era

Carl Danzig, MD, FASRS; Sruthi Arepalli, MD; Priya Vakharia, MD, FASRS

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

Trending on Eye Care Network - Ophthalmology Times

Retinal imaging as a window into atrial fibrillation

OCT-980 receives FDA orphan drug designation for retinitis pigmentosa

First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP

Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery

The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD